Document:

Exhibit
4.1

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

AMEDICA
CORPORATION 

 

	Warrant
    Shares: 100,000	Initial
    Issuance Date: April 4, 2016

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Riverside Merchant Partners,
LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and
the conditions hereinafter set forth, at any time from the six (6) month anniversary of the Initial Issuance Date (the “Initial
Exercise Date”) and on or prior to the close of business on the five-year anniversary of the Initial Exercise Date (the
“Termination Date”) but not thereafter, to subscribe for and purchase from Amedica Corporation, a Delaware
corporation (the “Company”), up to 100,000 shares (subject to adjustment hereunder, the “Warrant Shares”)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).

 

Section
1.Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings
set forth in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Alternate
Consideration” shall have the meaning ascribed to such term in Section 3(e).

 

“Base
Share Price” shall have the meaning ascribed to such term in Section 3(b).

 

“Beneficial
Ownership Limitation” shall have the meaning ascribed to such term in Section 2(e).

 

    	 	 	 

     

    

 

“Bloomberg”
means Bloomberg, L.P.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.

 

“Black
Scholes Value” shall have the meaning ascribed to such term in Section 3(e).

 

“Buy-In”
shall have the meaning ascribed to such term in Section 2(d)(iv).

 

“Closing
Bid Price” and “Closing Sale Price” shall mean for any security as of any date, the last closing
bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or,
if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing
trade price, as the case may be, then the last bid price or last trade price, respectively, of such security prior to 4:00:00
p.m., New York Time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading
market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities
exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply,
the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic
bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported
for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such
security as reported in the OTC Link or “pink sheets” by OTC Markets Group Inc. (formerly the Pink OTC Markets Inc.).
If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing
bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market
value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market
value of such security, then such dispute shall be resolved in good faith by the Holder pursuant to Section 17. All such
determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar
transaction during the applicable calculation period.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.01 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

 

    	 	2	 

     

    

 

“Company”
shall have the meaning ascribed to such term in the Preamble.

 

“Distribution”
shall have the meaning ascribed to such term in Section 3(d).

 

“DWAC”
shall have the meaning ascribed to such term in Section 2(d).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Exempt
Issuance” shall have the meaning ascribed to such term in Section 3(b).

 

“Exercise
Price” shall have the meaning ascribed to such term in Section 2(b).

 

“Fundamental
Transaction” shall have the meaning ascribed to such term in Section 3(e).

 

“Holder”
shall have the meaning ascribed to such term in the Preamble.

 

“Initial
Exercise Date” has the meaning set forth on page 1 of this Warrant

 

“Person”
means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation,
limited liability company, institution, entity, party or government (whether national, federal, state, county, city, municipal
or otherwise including, without limitation, any instrumentality, division, agency, body or department thereof).

 

“Purchase
Rights” shall have the meaning ascribed to such term in Section 3(c).

 

“Registration
Statement” shall have the meaning ascribed to such term in Section 5(o).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Subsidiary”
means any direct and/or indirect, wholly owned or partially owned subsidiary of the Company or a subsidiary of any subsidiary
and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

 

“Successor
Entity” shall have the meaning ascribed to such term in Section 3(e).

 

“Termination
Date” shall be five years after the Initial Exercise Date.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

    	 	3	 

     

    

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock (or any other common stock of any
other Person that references the Trading Market for its common stock) is listed or quoted for trading on the date in question:
the OTC Bulletin Board; The NASDAQ Global Market; The NASDAQ Global Select Market; The NASDAQ Capital Market, the New York Stock
Exchange; NYSE Arca; the NYSE MKT; or the OTCQX Marketplace; the OTCQB Marketplace; the OTCPink Marketplace or any other tier
operated by OTC Markets Group Inc. (or any successor to any of the foregoing).

 

“VWAP”
means, for or as of any date, the dollar volume-weighted average price for such security on the Trading Market (or, if the Trading
Market is not the principal trading market for such security, then on the principal securities exchange or securities market on
which such security is then traded) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New
York time, as reported by Bloomberg through its “HP” function (set to weighted average) or, if the foregoing does
not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin
board for such security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time,
as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours,
the average of the highest Closing Bid Price and the lowest closing ask price of any of the market makers for such security as
reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated
for such security on such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market
value as mutually determined by the Company and the Holder. All such determinations shall be appropriately adjusted for any stock
dividend, stock split, stock combination, recapitalization or other similar transaction during such period.

 

“Warrant”
shall have the meaning ascribed to such term in the Preamble.

 

“Warrant
Register” shall have the meaning ascribed to such term in Section 4(c).

 

“Warrant
Share Delivery Date” shall have the meaning ascribed to such term in Section 2(d).

 

“Warrant
Shares” means the shares of Common Stock issuable upon exercise of the Warrants.

 

    	 	4	 

     

    

 

Section
2.Exercise.

 

a)Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or
agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing
on the books of the Company) of a duly executed facsimile copy of the Notice of Exercise form annexed hereto and within three
(3) Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received payment of the
aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder
and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of
lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one (1) Business Day of receipt
of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

b)Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $1.62, subject to adjustment hereunder
(the “Exercise Price”).

 

c)Cashless
Exercise. If at any time there is no effective registration statement registering, or no current prospectus available for,
the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by
means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to
the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

	 	(A)
=	the VWAP on
          the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
          exercise,” as set forth in the applicable Notice of Exercise;
	 	 	 
	 	(B) =	the
                                         Exercise Price of this Warrant, as adjusted hereunder; and
	 	 	 
	 	(X) =	the
                                         number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                         with the terms of this Warrant if such exercise were by means of a cash exercise rather
                                         than a cashless exercise.

 

    	 	5	 

     

    

 

d)
Mechanics of Exercise.

 

i.Delivery
of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder
by crediting the account of the Holder’s prime broker with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder
or (B) the shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and
otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three (3)
Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise and (B) surrender of this Warrant (if
required) (such date, the “Warrant Share Delivery Date”). The Warrant Shares shall be deemed to have been issued,
and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares
for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price and all taxes
required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid.
If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue)
for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Warrant Shares shall bear a restrictive legend in the following form, as appropriate:

 

“NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN
A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE
144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

    	 	6	 

     

    

 

ii.Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

iii.Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before
the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction
or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a
sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. Notwithstanding
anything to the contrary contained in this Section 2(d)(iv), the Company shall pay cash to the Holder under this Section 2(d)(iv),
in an amount not to exceed $100,000, so long as there is no material default under that certain Loan and Security Agreement dated
as of June 30, 2014 (the “Term Loan”), by and among the Company, Hercules Technology III, L.P., a Delaware limited
partnership and Hercules Capital, Inc. (fka, Hercules Technology Growth Capital, Inc.), a Maryland corporation, as such agreement
may be amended from time to time. In the event that there is a material default under the Term Loan, the cash payment(s) (including
without limitation any and all applicable penalties and late fees), which shall not be subject to the $100,000 maximum in the
foregoing sentence, shall be deferred until the lenders under the Term Loan are paid in full.

 

    	 	7	 

     

    

 

v.No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi.Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise.

 

vii.Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.

 

    	 	8	 

     

    

 

e)Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own
in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares
of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable
upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned
by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as
set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion
of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above
shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number
of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with
the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request
of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect
to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the
date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation”
shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’ prior notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership
Limitation in no event exceeds 19.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section
2(e) shall continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice
is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary
or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of this Warrant.

 

    	 	9	 

     

    

 

Section
3.Certain Adjustments.

 

a)Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)[Reserved]

 

c)Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the
Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right
to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and
such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    	 	10	 

     

    

 

d)Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

e)Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard
to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction that is (1) an all
cash transaction, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act, or (3) a Fundamental
Transaction involving a person or entity not traded on a national securities exchange and only if such Fundamental Transaction
is within the Company’s control, the Company or any Successor Entity (as defined below) shall, at the Holder’s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase
this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised
portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, if the Fundamental
Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder
shall not have the option to require the Company to purchase its Warrant. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the
obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(e) pursuant to written agreements prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the
Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant
(without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of
the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the
Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for
(so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents
referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of
the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with
the same effect as if such Successor Entity had been named as the Company herein. For the avoidance of doubt, if, at any time
while this Warrant is outstanding, a Fundamental Transaction occurs, pursuant to the terms of this Section 5(e), the Holder shall
not be entitled to receive more than one of (i) the consideration receivable as a result of such Fundamental Transaction by a
holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction,
(ii) an amount of cash equal to the Black Scholes Value of the remaining unconverted portion of this Warrant on the date of the
consummation of such Fundamental Transaction, or (iii) the assumption by the Successor Entity of all of the obligations of the
Company under this Warrant and the other Transaction Documents and the option to receive a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant. Notwithstanding anything to the contrary
contained in this Section 3(e), in the event that the Company must pay cash to the Holder under this Section 3(e) it may do so
in an amount not to exceed $100,000, so long as there is no material default under the Term Loan. In the event that there is a
material default under the Term Loan, the cash payment(s) (including without limitation any and all applicable penalties and late
fees), which shall not be subject to the $100,000 maximum in the foregoing sentence, shall be deferred until the lenders under
the Term Loan are paid in full.

 

    	 	11	 

     

    

 

“Black
Scholes Value” means the value of the unexercised portion of this Warrant remaining on the date of the Holder’s
request pursuant to Section 3(e) which value is calculated using the Black Scholes Option Pricing Model for a “call”
or “put” option, as elected by the Holder, as obtained from the “OV” function on Bloomberg utilizing (i)
an underlying price per share equal to the greater of (1) the highest Closing Sale Price of the Common Stock during the period
beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation
of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to
Section 3(e) and (2) the sum of the price per share being offered in cash in the applicable Fundamental Transaction (if any) plus
the value of the non-cash consideration being offered in the applicable Fundamental Transaction (if any), (ii) a strike price
equal to the Exercise Price in effect on the date of the Holder’s request pursuant to Section 3(e), (iii) a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the greater of (1) the remaining term of this Warrant as of
the date of the Holder’s request pursuant to Section 3(e) and (2) the remaining term of this Warrant as of the date of consummation
of the applicable Fundamental Transaction or as of the date of the Holder’s request pursuant to Section 3(e) if such request
is prior to the date of the consummation of the applicable Fundamental Transaction, (iv) a zero cost of borrow and (v) an expected
volatility equal to the greater of 100% and the 30 day volatility obtained from the “HVT” function on Bloomberg (determined
utilizing a 365 day annualization factor) as of the Trading Day immediately following the earliest to occur of (A) the public
disclosure of the applicable Fundamental Transaction, (B) the consummation of the applicable Fundamental Transaction and (C) the
date on which the Holder first became aware of the applicable Fundamental Transaction.

 

f)Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)Notice
to Holder.

 

3)Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the
number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

4)Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing
thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice except as may otherwise be expressly set forth herein.

 

    	 	12	 

     

    

 

Section
4.Transfer of Warrant.

 

a)Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof, this Warrant and
all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender
of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder
delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith,
may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b)New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial
Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

    	 	13	 

     

    

 

c)Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

 

d)Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and
under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or
current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5(k).

 

e)Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.

 

Section
5.Miscellaneous.

 

a)No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
Section 3.

 

b)Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

    	 	14	 

     

    

 

c)Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

d)Authorized
Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares
of Common Stock a number of shares of Common Stock equal to the product of (i) 125% multiplied by (ii) the maximum number of shares
of Common Stock issuable upon exercise of this Warrant assuming the exercise price of this Warrant is $1.62 taking into account
any anti-dilution adjustments but excluding any Beneficial Ownership Limitations and/or other limitations or the exercise of this
Warrant solely for the purpose of calculations under this Section 5(d) only. The Company further covenants that its issuance of
this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares
upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary
to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or
of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights
represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

    	 	15	 

     

    

 

e)Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law
thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of
New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City
of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of the Warrants, then, the prevailing party in such action, suit or proceeding shall
be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action, suit or proceeding.

 

f)Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions
upon resale imposed by state and federal securities laws.

 

g)Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that
all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision
of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall
be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those
of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of
its rights, powers or remedies hereunder.

 

h)Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
via U.S. First Class Mail to the address specified below, or to such other address as either such party shall hereafter specify
in writing to the other:

 

    	 	16	 

     

    

  

	 	For
    Holder:	 
	 	Name:	David
    Bocchi, Member
	 	Address:
    	810
    7th Avenue, 18th Floor
	 		New
    York, NY 10019 
	 	 	 
	 	Telephone
    Number: 	(212)
    813-2029
	 	Email:	db@riversidemp.com
	 	 	 
	 	For
    Company:	 
	 	Name:	Ty
    Lombardi, Chief Financial Officer
	 	Address:
    	1885
    West 2100 South
	 	 	 
	 		Salt
    Lake City, UT 84119 
	 	 	 
	 	Telephone
    Number: 	(801)
    839-3500
	 	Email:	TLombardi@amedica.com

  

i)Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

j)Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

k)Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.

 

l)Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m)Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

n)Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	 	17	 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	Amedica
    Corporation
	 	 
	 	By:	 
	 	Name:	
	 	Title:
    	

 

[Signature
Page to Common Stock Purchase Warrant]

  

    	 	 	 

     

    

 

NOTICE
OF EXERCISE

 

To:Amedica
Corporation

 

(1)The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.

 

(2)Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

  

 

 

 

 

 

 

(3)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under
the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

  

Name
of Investing Entity: ________________________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

 

Name
of Authorized Signatory: ___________________________________________________________________

 

Title
of Authorized Signatory: ____________________________________________________________________

 

Date:
________________________________________________________________________________________

 

    	 	 	 

     

    

 

EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please
    Print)
	 	 
	Address:	 
	 	(Please
    Print)

 

Dated:
___________ __, ______

Holder’s
Signature:___________

Holder’s
Address:____________Exhibit
10.1

 

PAYMENT
OF THE ASSIGNED LOAN IS SUBJECT TO A SUBORDINATION AGREEMENT DATED APRIL 4, 2016, BETWEEN HERCULES, BORROWER AND ASSIGNEE, AND
NO PAYMENTS THEREOF MAY BE MADE EXCEPT AS PROVIDED IN SUCH SUBORDINATION AGREEMENT. A COPY OF THE SUBORDINATION AGREEMENT IS AVAILABLE
FROM HERCULES ON WRITTEN REQUEST.

 

ASSIGNMENT
AGREEMENT

AND

SECOND
AMENDMENT TO LOAN AND SECURITY AGREEMENT

 

This
Assignment Agreement and Second Amendment to Loan and Security Agreement (the “Assignment Agreement”) is dated
as April 4, 2016 (the “Effective Date”) by and among Amedica Corporation, a Delaware corporation (“Borrower”),
Riverside Merchant Partners, LLC (“Assignee”), Hercules Technology III, L.P., a Delaware limited partnership
(“HT III”), and Hercules Capital, Inc. (fka, Hercules Technology Growth Capital, Inc.), a Maryland corporation
(“HC” and together with HT III “Hercules”).

 

WHEREAS,
Hercules entered into that certain Loan and Security Agreement with Borrower dated as of June 30, 2014, as amended from time to
time (the “Agreement”). All capitalized terms used but not otherwise defined in this Assignment Agreement shall
have the meaning provided in the Agreement;

 

WHEREAS,
HT III and HC each desire to assign One Million Five Hundred Thousand Dollars (($1,500,000), for an aggregate amount of Three
Million Dollars ($3,000,000)) of the principal amount of the Term Loan to Assignee, and Assignee desires to purchase such amounts
and accept the assignment, all in accordance with the terms of this Assignment Agreement;

 

WHEREAS,
Borrower consents to such purchase by and assignment to Assignee; and

 

NOW,
THEREFORE, based on the mutual promises provided herein and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, Assignee, Borrower and Hercules agree as follows:

 

1.
Assignment.

 

a.
First Assignment. On payment by Assignee of Five Hundred Thousand Dollars ($500,000) to HT III and Five Hundred Thousand
Dollars ($500,000) to HC, HT III and HC, jointly and not severally, hereby each assign to Assignee Five Hundred Thousand Dollars
($500,000) of the principal amount of their respective Term Loan (collectively, the “First Assigned Loan”).
The First Assigned Loan does not include any right to receive (i) payment of any part of (A) accrued but unpaid interest, (B)
the closing fee paid under Section 2.6(a) of the Agreement, (C) the end of term fee required to be paid under Section
2.6(b) of the Agreement, or (D) any other fees or charges paid or to be paid to Hercules under the Agreement, or (ii) any
portion of the Warrants. The First Assigned Loan shall, however, be secured by the Collateral to the same extent that the Collateral
secures the Term Loan. Payment for the First Assigned Loan shall be made by wire transfer to Hercules on the Effective Date pursuant
to the wire transfer instructions provided on Schedule 1.a hereto.

 

b.
Second Assignment. At Assignee’s option, on payment by Assignee of One Million Dollars ($1,000,000) to HT III and
One Million Dollars ($1,000,000) to HC, HT III and HC, jointly and not severally, hereby each assign to Assignee One Million Dollars
($1,000,000) of the principal amount of their respective Term Loan (collectively, the “Second Assigned Loan”;
the First Assigned Loan and the Second Assign Loan, collectively, the “Assigned Loan”). The Second Assigned
Loan does not include any right to receive (i) payment of any part of (A) accrued but unpaid interest, (B) the closing fee paid
under Section 2.6(a) of the Agreement, (C) the end of term fee required to be paid under Section 2.6(b) of the Agreement,
or (D) any other fees or charges paid or to be paid to Hercules under the Agreement, or (ii) any portion of the Warrants. The
Second Assigned Loan shall, however, be secured by the Collateral to the same extent that the Collateral secures the Term Loan.
In order to exercise the option to acquire the Second Assigned Loan, Assignee must be provide written notice to Hercules so that
(y) such notice is received within twenty (20) trading days of the Effective Date, and (z) payment for the Second Assigned Loan
is received by wire transfer to Hercules within one (1) business day of such notice pursuant to the wire transfer instructions
provided on Schedule 1.a hereto.

 

    	 	 	 

     

    

 

c.
Assignee agrees that its right to receive payments of principal, interest or any other amounts related to or arising under the
Assigned Loan shall be subordinated to the full payment of all Obligations owed Hercules, and in furtherance thereof, Assignee
shall on the date hereof sign and deliver a subordination agreement in substantially the form attached hereto as Exhibit A (the
“Subordination Agreement”). Assignee agrees that the provisions of this Assignment Agreement and the Subordination
Agreement control over the provisions of Section 10.1(a) of the Agreement that provide that the Assignee would be entitled
to the same rights and benefits as Hercules. Assignee shall, however, be allowed to convert all or a portion of the Assigned Loan
plus accrued but unpaid interest (including, without limitation PIK interest) into Borrower’s capital stock, warrants, or
other convertible security at any time. Accordingly, Hercules hereby consents to the exchange transactions contemplated in that
certain Exchange Agreement dated as of even date herewith, between Borrower and Assignee.

 

d.
So long as no Event of Default has occurred or is continuing, Borrower shall pay regularly scheduled interest on the Assigned
Loan as provided in the Agreement. On the occurrence and during the continuation of an Event of Default, no payments in cash shall
be made on account of the Assigned Loan. Borrower shall make no payments of Assigned Loan principal or other amounts under the
Loan Agreement (other than regularly scheduled interest as allowed under the first sentence of this Subsection 1(d)) to
Assignee as long as any Obligations remain outstanding to Hercules. Until all Obligations owed to Hercules are repaid in full,
any principal of the Assigned Loan or other amounts (other than regularly scheduled interest) that would otherwise be required
to be paid to Assignee under the Agreement shall simply be deferred. If any interest or other amounts (other than principal) are
not paid, such amounts shall instead be added to the principal balance of the Assigned Loan, with interest to accrue on the principal
balance at the interest rate applicable under the Agreement.

 

e.
To the extent that any payments are permitted to be made to Assignee by Borrower, such payments shall be made directly to Assignee
and not through HC as Agent under the Agreement. Assignee and Borrower shall be responsible for keeping accurate records of the
Obligations related to the Assigned Loan, and neither HT III nor HC, whether as Lenders or as Agent, shall have any bookkeeping,
information delivery or other requirements or duties to Assignee under the Loan Documents.

 

f.
Upon payment in full of the Obligations to Hercules and provided that some or all of a portion of the Assigned Loan remains outstanding,
Hercules shall be deemed to assign, transfer and convey to Assignee (i) the Loan Documents other than the Warrants, and (ii) all
rights as Agent under the Loan Documents.

 

g.
The assignment of the Assigned Loans is without recourse to Hercules.

 

h.
On the Effective Date, Schedule A to the Agreement is amended and restated as provided in Schedule A attached hereto.

 

i.
Except for rights specifically assigned hereunder, HT III and HC shall retain all rights under the Loan Documents.

 

    	 	 	 

     

    

 

2.
Representations and Warranties.

 

a.
Assignee. The Assignee (i) represents and warrants that (A) it is legally authorized to enter into this Assignment Agreement;
(B) it has obtained all consents and approvals required to enter into this Assignment Agreement; (C) this Assignment Agreement
is binding legal obligation of Assignee, enforceable against it in accordance with this Assignment Agreement’s terms, except
as enforceability may be limited by applicable bankruptcy, insolvency, or similar laws affecting the enforcement of creditors’
rights generally or by equitable principles relating to enforceability; (D) from and after the Effective Date, it shall be bound
by the provisions of the Agreement as a Lender thereunder and, to the extent of the Assigned Loan, shall have the obligations
of a Lender thereunder; (E) it is sophisticated with respect to decisions to acquire assets of the type represented by such Assigned
Loan and either it, or the Person exercising discretion in making its decision to acquire such Assigned Loan, is experienced in
acquiring assets of such type; (F) it has, independently and without reliance upon Hercules and based on such documents and information
as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment Agreement to purchase such
Assigned Loan; and (G) it is not prohibited from being a Lender; (ii) confirms that, based on Borrower’s and Hercules’
representation, it has received a copy of the Loan Documents other than the Warrant, together with copies of the most recent financial
statements delivered pursuant to Section 6.3 of the Agreement and such other documents and information as it has deemed appropriate
to make its own credit analysis and decision to enter into this Assignment and Acceptance; (iii) will independently and without
reliance upon Hercules and based on such documents and information as it shall deem appropriate at the time, continue to make
its own credit decisions in taking or not taking action permitted to be taken under the Loan Documents (excluding the Warrants);
(iv) appoints and authorizes Agent to take such action as agent on its behalf and to exercise such powers under the Agreement
as are delegated to Agent by the terms of the Agreement; and (v) agrees that it will perform in accordance with their terms all
the obligations which by the terms of the Loan Documents (excluding the Warrants) are required to be performed by it as a Lender.

 

b.
Hercules. HT III and HC, jointly and not severally, represents and warrants that (i) it is legally authorized to enter
into this Assignment Agreement, (ii) it has obtained all consents and approvals required to enter into this Assignment Agreement,
(iii) this Assignment Agreement is binding legal obligation of Hercules, enforceable against it in accordance with this Assignment
Agreement’s terms, except as enforceability may be limited by applicable bankruptcy, insolvency, or similar laws affecting
the enforcement of creditors’ rights generally or by equitable principles relating to enforceability, (iv) it is the legal
and beneficial owner of the interest being assigned thereby free and clear of any adverse claim, (v) to Hercules’ knowledge,
the Loan Documents were duly authorized, executed, delivered and performed pursuant to all requisite corporate action on behalf
of Hercules, and in accordance with all applicable law, including, without limitation, federal, state and securities law, (vi)
to Hercules’ knowledge, no Event of Default has occurred and is continuing, (vii) they are sophisticated with respect to
decisions to acquire assets of the type represented by such Assigned Loan and either they, or the Person exercising discretion
in making their decision to sell such Assigned Loan, is experienced in disposing of assets of such type; (viii) they have, independently
and without reliance upon Assignee and based on such documents and information as they have deemed appropriate, made their own
credit analysis and decision to enter into this Assignment Agreement to sell such Assigned Loan, (ix) they will independently
and without reliance upon Assignee and based on such documents and information as they shall deem appropriate at the time, continue
to make their own credit decisions in taking or not taking action permitted to be taken under the Loan Documents, and (x) the
Assignee has received a complete, fully executed set of all the Loan Documents, as amended to date. Except as set forth in this
Section (b)(i)-(x), HT III and HC make no representations or warranties and assume no responsibility with respect to any statements,
warranties or representations made in or in connection with the Loan Documents, or the execution, legality, validity, enforceability,
genuineness, sufficiency or value of the Loan Documents or any other instrument or document furnished pursuant to the Loan Documents,
or the financial condition of, Borrower or any of its Subsidiaries or the performance or observance by Borrower or any such Subsidiary
of any of its obligations under the Loan Documents or any other instrument or document furnished pursuant thereto. Except for
the representations and warranties provided in this Section 2(b)(i)-(vi), the Assigned Loan is sold and assigned “as is”
and “where is” without representations or warranties of any kind, including without limitation, warranties of merchantability
or fitness of purpose.

 

    	 	 	 

     

    

 

c.
Borrower. Borrower represents and warrants that (i) it is legally authorized to enter into this Assignment Agreement, (ii)
it has obtained all consents and approvals required to enter into this Assignment Agreement, (iii) this Assignment Agreement is
binding legal obligation of Borrower, enforceable against it in accordance with this Assignment Agreement’s terms, except
as enforceability may be limited by applicable bankruptcy, insolvency, or similar laws affecting the enforcement of creditors’
rights generally or by equitable principles relating to enforceability, (iv) the Loan Documents were duly authorized, executed,
delivered and performed pursuant to all requisite corporate action on behalf of Borrower and in accordance with all applicable
law, including, without limitation, all federal and state securities law, (vi) Borrower has delivered to Assignee Borrower’s
most recent financial statements delivered pursuant to Section 6.3 of the Agreement.

 

3.
End of Term Fee. Borrower agrees that notwithstanding the existing language of Section 2.6(b) of the Agreement,
Subsection 2.6(b)(ii) shall be read to mean the date that Borrower prepays the Obligations without reference to the portion
of the Obligations related to the Assigned Loan, it being the intent that the end of term fees shall be due to Hercules under
that subsection when the Obligations due to Hercules have been paid in full.

 

4.
Consent and Approval. Borrower hereby approves the foregoing Assignment Agreement, the modifications to the Agreement made
herein, and the sale and assignment of the Assigned Loan to Assignee.

 

5.
General Provisions.

 

a.
Severability. Whenever possible, each provision of this Assignment Agreement shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Assignment Agreement shall be prohibited by or invalid
under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this Assignment Agreement.

 

b.
Notice. Any notice or service of process or other communication shall be in writing, and shall be deemed to have been validly
served, given, delivered, and received upon the earlier of: (i) the day of transmission if sent by facsimile or email, (ii) the
day of delivery if hand delivered or delivered by an overnight express service or overnight mail delivery service, in each case
addressed to the party to be notified as follows:

 

(a)
If to HT III:

 

HERCULES
TECHNOLOGY III, L.P.

Legal
Department

Attention:
Chief Legal Officer

400
Hamilton Avenue, Suite 310

Palo
Alto, CA 94301

Facsimile:
650-473-9194

Telephone:
650-289-3060

Email:
bbang@herculestech.com

 

    	 	 	 

     

    

 

(b)
If to HC:

 

HERCULES
CAPITAL, INC.

Legal
Department

Attention:
Chief Legal Officer

400
Hamilton Avenue, Suite 310

Palo
Alto, CA 94301

Facsimile:
650-473-9194

Telephone:
650-289-3060

Email:
bbang@herculestech.com

 

(c)
If to Assignee:

 

Riverside
Merchant Partners, LLC

810
7th Avenue, 18th Floor

New
York, NY 10019

Facsimile:

Telephone:
212-813-2029

Email:
db@riversidemp.com

 

(d)
If to Borrower:

 

Amedica
Corporation

1885
West 2100 South

Salt
Lake City, UT 84119

Facsimile:
801-683-2805

Telephone:
801-839-3516

Email:
tlombardi@amedica.com

 

or
to such other address as each party may designate for itself by like notice.

 

c.
Entire Agreement; Amendments. This Assignment Agreement and the agreements referenced herein, constitute the entire agreement
and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their
entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with
respect to the subject matter hereof or thereof. None of the terms of this Assignment Agreement may be amended except by an instrument
executed by each of the parties hereto.

 

d.
No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement.
In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly
by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement.

 

    	 	 	 

     

    

 

e.
No Waiver. No omission or delay by Hercules or Assignee at any time to enforce any right or remedy reserved to it, or to
require performance of any of the terms, covenants or provisions hereof by Assignee at any time designated, shall be a waiver
of any such right or remedy to which such party is entitled, nor shall it in any way affect such party’s right to enforce
such provisions thereafter.

 

f.
Survival. All agreements, representations and warranties contained in this Assignment Agreement or in any document delivered
pursuant hereto or thereto shall survive the execution and delivery of this Assignment Agreement.

 

g.
Governing Law. This Assignment Agreement has been negotiated and delivered to Hercules in the State of California, and
shall have been accepted by Hercules in the State of California. Payment to Hercules is due in the State of California. This Assignment
Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding
conflict of laws principles that would cause the application of laws of any other jurisdiction.

 

h.
Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of Section 5(i)
is not applicable) arising in or under or related to this Assignment Agreement may be brought in any state or federal court located
in the State of California. By execution and delivery of this Assignment Agreement, each party hereto generally and unconditionally:
(i) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (ii) waives any objection as to
jurisdiction or venue in Santa Clara County, State of California; (iii) agrees not to assert any defense based on lack of jurisdiction
or venue in the aforesaid courts; and (iv) irrevocably agrees to be bound by any judgment rendered thereby in connection with
this Assignment Agreement. Service of process on any party hereto in any action arising out of or relating to this Assignment
Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 5(b), and shall be deemed
effective and received as set forth in Section 5(b). Nothing herein shall affect the right to serve process in any other manner
permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

 

i.
Mutual Waiver of Jury Trial / Judicial Reference.

 

(A)
Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced
and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties
desire that their disputes be resolved by a judge applying such applicable laws. EACH OF ASSIGNEE AND HERCULES SPECIFICALLY WAIVES
ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER
CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY OR AGAINST EACH OTHER UNDER THIS ASSIGNMENT AGREEMENT. This waiver extends
to all such Claims, including Claims that involve Persons other than Assignee and Hercules, and any Claims for damages, breach
of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Assignment Agreement.

 

    	 	 	 

     

    

 

(B)
If the waiver of jury trial set forth in Section 5(i)(A) is ineffective or unenforceable, the parties agree that all Claims shall
be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a
mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of Santa Clara County,
California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery
applicable to such proceeding.

 

(C)
In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 5(h) any
prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted
by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.

 

j.
Counterparts. This Assignment Agreement and any amendments, waivers, consents or supplements hereto may be executed in
any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be
deemed an original, but all of which counterparts shall constitute but one and the same instrument.

 

k.
No Third Party Beneficiaries. No provisions of this Assignment Agreement are intended, nor will be interpreted, to provide
or create any third-party beneficiary rights or any other rights of any kind in any Person other than HT III, HC, Assignee and
Borrower unless specifically provided otherwise herein.

 

[Remainder
of page intentionally left blank]

 

    	 	 	 

     

    

 

The
terms set forth in this Assignment Agreement and Second Amendment to Loan and Security Agreement are hereby agreed to as of the
date first provided above.

 

	HERCULES
    CAPITAL, INC.	 
	 	 	 
	Signature:	 	 
	Print
    Name:		 
	Title:		 

 

	HERCULES
                                         TECHNOLOGY III, L.P.

                                                                      a
                                         Delaware limited partnership
	 
	 	 
	By:
    	Hercules
    Technology SBIC 

    Management, LLC, its General 

    Partner	 
	 	 	 
	By:
    	Hercules
    Capital, Inc., its 

    Manager	 

 

	Signature:	 	 
	Print
    Name:		 
	Title:		 
	 	 	 
	RIVERSIDE
    MERCHANT PARTNERS, LLC	 
	 	 	 
	Signature:
    	 	 
	Print
    Name: 		 
	Title:		 
	 	 	 
	AMEDICA
    CORPORATION	 
	 	 	 
	Signature:		 
	Print
    Name:		 
	Title:	                                 	 

 

[Signature
Page to Assignment Agreement and Second Amendment to Loan and Security Agreement]

 

    	 	 	 

     

    

 

Schedule
A

 

COMMITMENTS

 

As
of June 30, 2014:

 

	Name of Lender	 	Term Loan Commitment	 	Pro Rata Share of Term Loan
    Commitments	 	Total Commitments	 	Pro Rata Share of Commitments
	Hercules Technology Growth Capital, Inc.	 	$	10,000,000	 	 	 	50.0	%	 	$	10,000,000	 	 	 	50.0	%
	Hercules Technology III, L.P.	 	$	10,000,000	 	 	 	50.0	%	 	$	10,000,000	 	 	 	50.0	%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	TOTAL	 	$	20,000,000	 	 	 	100	%	 	$	20,000,000	 	 	 	100	%

 

As
of the First Assignment Date (defined below):

 

	Name of Lender	 	Term Loan Commitment	 	Pro Rata Share of Term Loan
    Commitments	 	Total Commitments	 	Pro Rata Share of Commitments
	Hercules Capital, Inc. (fka, Hercules Technology Growth Capital, Inc.)	 	$	9,500,000	 	 	 	47.5	%	 	$	9,500,000	 	 	 	47.5	%
	Hercules Technology III, L.P.	 	$	9,500,000	 	 	 	47.5	%	 	$	9,500,000	 	 	 	47.5	%
	Riverside Merchant Partners, LLC	 	$	1,000,000	 	 	 	5.0	%	 	$	1,000,000	 	 	 	5.0	%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	TOTAL	 	$	20,000,000	 	 	 	100	%	 	$	20,000,000	 	 	 	100	%

 

As
of the Second Assignment Date (defined below):

 

	Name of Lender	 	Term Loan Commitment	 	Pro Rata Share of Term Loan
    Commitments	 	Total Commitments	 	Pro Rata Share of Commitments
	Hercules Capital, Inc., (fka, Hercules Technology Growth Capital, Inc.)	 	$	8,500,000	 	 	 	42.5	%	 	$	8,500,000	 	 	 	42.5	%
	Hercules Technology III, L.P.	 	$	8,500,000	 	 	 	42.5	%	 	$	8,500,000	 	 	 	42.5	%
	Riverside Merchant Partners, LLC	 	$	3,000,000	 	 	 	15.0	%	 	$	3,000,000	 	 	 	15.0	%
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	TOTAL	 	$	20,000,000	 	 	 	100	%	 	$	20,000,000	 	 	 	100	%

 

The
First Assignment Date shall occur, if at all, on the closing of the First Assigned Loan (as that term is defined in that certain
Assignment Agreement and Second Amendment to Loan and Security Agreement dated as of April 4, 2016, by and among Borrower, Agent,
HTGC, HT III and Riverside Merchant Partners, LLC).

 

The
Second Assignment Date shall occur, if at all, on the closing of the Second Assigned Loan (as that term is defined in that certain
Assignment Agreement and Second Amendment to Loan and Security Agreement dated as of April 4, 2016, by and among Borrower, Agent,
HTGC, HT III and Riverside Merchant Partners, LLC).

 

    	 	 	 

     

    

 

Exhibit
A

 

Form
of Subordination Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]